Abstract
OBJECTIVE
Sunitinib is a tyrosine kinase inhibitor used in the therapy of pancreatic neuroendocrine tumors (PNETs), metastatic renal cancer and gastrointestinal stromal tumors. We describe a patient with PNET who presented with severe hypoglycemia following sunitinib administration.
CASE REPORT
A 64-year old man with known metastatic PNET presented with a history of recurring episodes of severe, life-threatening hypoglycemia 3 months after initiation of sunitinib treatment. Investigations during symptomatic hypoglycemia revealed inappropriately increased plasma insulin and C-peptide levels, consistent with endogenous hyperinsulinemia. No immune staining for insulin was observed in tissue samples from peritoneal metastatic tumor lesions, and serum anti-insulin antibodies were negative. Medical management with diazoxide, methylprednisolone and ocreotide was ineffective; continuous intravenous infusion of glucagon was required to maintain euglycemia. Following discontinuation of sunitinib there was gradual improvement in both the severity and frequency of the hypoglycemia. Six months later, the patient remained free of hypoglycemic episodes.
CONCLUSIONS
We describe a patient with PNET who experienced severe, life-threatening hypoglycemia following sunitinib use. It is important that glucose levels of patients treated with sunitinib are monitored on a regular basis; those patients with diabetes may need to have their antidiabetic treatment adjusted to prevent hypoglycemia.
Article PDF
Similar content being viewed by others
References
Klöppel G, Perren A, Heitz PU, 2004 The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014: 13–27.
Strosberg JR, 2014 Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Endocr Pract 20: 167–175.
Raymond E, Dahan L, Raoul JL, et al, 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501–513.
Chen J, Wang C, Han J, et al, 2013 Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther 13: 737–743.
Agostino NM, Chinchilli VM, Lynch CJ, et al, 2011 Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 17: 197–202.
Cryer PE, Axelrod L, Grossman AB, et al, 2009 Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 94: 709–728.
Chow LQ, Eckhardt SG, 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884–896.
Subbiah V, Meric-Bernstam F, Mills GB, et al, 2014 Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol 7: 52.
Kogan M, Fischer-Smith T, Kaminsky R, Lehmicke G, Rappaport J, 2012 CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines. Anticancer Res 32: 893–899.
Carr LL, Mankoff DA, Goulart BH, et al, 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16: 5260–5268.
Massicotte MH, Brassard M, Claude-Desroches M, et al, 2014 Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 170: 575–582.
Billemont B, Medioni J, Taillade L, et al, 2008 Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 99: 1380–1382.
Oh JJ, Hong SK, Joo YM, et al, 2012. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 42: 314–317.
Louvet C, Szot GL, Lang J, et al, 2008 Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 105: 18895–18900.
Huda MS, Amiel SA, Ross P, Aylwin SJ, 2014 Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care 37: 87–88.
Templeton A, Brandie M, Cerny T, Gillessen S, 2008 Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 19: 824–825.
Hagerkvist R, Sandler S, Mokhtari D, Welsh N, 2007 Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21: 618–628.
Veneri D, Franchini M, Bonora E, 2005 Imatinib and regression of type 2 diabetes. N Engl J Med 352: 1049–1050.
Hagerkvist R, Jansson L, Welsh N, 2008 Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 114: 65–71.
Chen H, Gu X, Liu Y, et al, 2011 PDGF signalling controls age-dependent proliferation in pancreatic beta-cells. Nature 478: 349–355.
Ohn JH, Kim YG, Lee SH, Jung HS, 2013 Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. Endocrinol Metab (Seoul) 28: 149–152.
Lee Y, Jung HS, Choi HJ, et al, 2011 Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report. Diabetes Res Clin Pract 93: 68–70.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fountas, A., Tigas, S., Giotaki, Z. et al. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones 14, 438–441 (2015). https://doi.org/10.14310/horm.2002.1560
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1560